Blog: The European Medicines Agency & The EU Brexit Summit
In this Acorn Regulatory blog, Brian Cleary looks ahead to the EU Brexit Summit and the news that the relocation of the EMA will incur a significant fee for the London offices of the agency.
SWOT Analysis of Ireland’s Bid for the European Medicines Agency
Dublin is regarded as the most likely city to host the European Medicines Agency in our first ever Brexit survey. In this blog post we look at Dublin and carry out a brief SWOT analysis of its capacity to host...
Brexit: Relocation of the European Medicines Agency
The triggering of Article 50 has caused the thoughts of many to turn to the issue of the relocation of the European Medicines Agency. In this blog update we look at the countries that have joined the race to host...
The Future of the European Medicines Agency
It could be argued that the European Medicines Agency is a bell weather for the plight of the Brexit negotiations. The Canary Wharf based agency is at the centre of much wooing from EU member states while the UK...
Who Will Host The European Medicines Agency?
For those of us working in the sector, the future location of the European Medicines Agency has been a consistent topic of conversation since the outcome of the Brexit vote became known.
Pharmacovigilance of Medicines for Rare Diseases
We look at the issue of pharmacovigilance for orphan or rare diseases. Many issues associated with the sector are challenged by the small patient population. This article looks at the commonly used strategies for evaluation of post-approval safety and the...
Most Read Brexit Articles of 2020
Acorn Regulatory has led the way in providing information and assistance to industry professionals since 2016. We have compiled some of the most read and useful articles in one place to help you to better understand how Brexit will impact...
What Are Post-Marketing Surveillance Studies?
Post-marketing surveillance studies are defined in Article 1(15) of Directive 2001/83/EC as studies carried out after a medicine has been authorised to obtain further information on a medicine’s safety or to measure the effectiveness of risk-management measures. In this article we...
Acorn Regulatory NewsAdvertisingComplianceEileen ShortissHow-To & ExplainersPharmaceuticalRegulatory Affairs
How To Improve The Readability of Package Leaflets
What changes could be made to the readability of package leaflets to make them more accessible for patients? Eileen Shortiss, a Senior Regulatory Affairs Advisor at Acorn Regulatory is our in-house expert on all matters relating to package information leaflets. ...
